Indications for: LONHALA MAGNAIR
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
For oral inhalation use only with Magnair device. Administer at the same time of the day (AM + PM). Inhale contents of one vial (25mcg) twice daily.
LONHALA MAGNAIR Warnings/Precautions:
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Labor & delivery. Pregnancy. Nursing mothers.
LONHALA MAGNAIR Classification:
LONHALA MAGNAIR Interactions:
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Dyspnea, urinary tract infection, wheezing, upper respiratory tract infection, nasopharyngitis, peripheral edema, fatigue; paradoxical bronchospasm, hypersensitivity reactions.
Generic Drug Availability:
Kit—60 vials (w. one Magnair device)